en · de · es · fr · pt
cardarine-notes.peptides4800.com › Guide › Background And Regulatory History — What the Evidence Shows

Background And Regulatory History — What the Evidence Shows

By Editorial Desk · published 2026-05-02 · last reviewed 2026-05-22 · Guide

This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Cardarine at a glance

PropertyValueNotes
Common nameCardarineCommon internet and media name.
Research codeGW501516Also written GW-1516.
Drug classPPARδ agonistNot a selective androgen receptor modulator.
Development statusDiscontinuedClinical development halted after rodent cancer findings.
Regulatory statusProhibited in sportListed by WADA; not approved as medicine.

Background and Research Context

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Related pages on this site

Detection, Regulation, and Quality Context

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Cardarine as Investigational PPARδ Agonist

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Identity and Pharmacological Mechanism

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

Supporting material

Mestanolone, also known as 17α-methyl-4,5α-dihydrotestosterone (17α-methyl-DHT) or as 17α-methyl-5α-androstan-17β-ol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of dihydrotestosterone (DHT). It differs from DHT only by the presence of the methyl group at the C17α position. Close synthetic relatives of mestanolone include oxandrolone (2-oxa-17α-methyl-DHT), oxymetholone (2-hydroxymethylene-17α-methyl-DHT), and stanozolol (a derivative of 17α-methyl-DHT (mestanolone) with a pyrazole ring fused to the A ring).

== Post-parliamentary career (2024–present) == In June 2025, Galloway renounced his opposition to Scottish independence, saying that he would now be in favour of a second referendum. Writing on X, he said: “We support the right of the Scots to self-determination. Eleven years after they last did so we believe the time for another referendum is close. Given the collapsing authority of the British state, the pitiful prime minister Starmer and the moral decline of British society, the result cannot easily be predicted. Britain has become a cesspit." This followed a comment Galloway had made on X in September 2024, in which he said: "You COULD persuade me to Scottish Independence, you could never persuade me to the SNP." In August 2025, Galloway announced that he would be contesting the 2026 Scottish Parliament election as the Workers Party candidate for Glasgow Southside. Additionally, he said that he would be second on the party list for the Glasgow region. In a press conference shortly after his election as MP for Rochdale in February 2024, Galloway had said that he was "no longer involved in Scottish politics", though did mention his support of the SNP's stance on Gaza, adding that they had been “outstanding on the Gaza question, at least by comparison with the two big parties of the state”. In light of this, he revealed that friend and lead candidate for Glasgow, Yvonne Ridley, had persuaded him to stand.

Epitheliomuscular cells whose bodies form part of the epithelium but whose bases extend to form muscle fibers in parallel rows. The fibers of the outward-facing cell layer generally run at right angles to the fibers of the inward-facing one. In Anthozoa (anemones, corals, etc.) and Scyphozoa (jellyfish), the mesoglea also contains some muscle cells. Cnidocytes, the harpoon-like "nettle cells" that give the phylum Cnidaria its name. These appear between or sometimes on top of the muscle cells. Nerve cells. Sensory cells appear between or sometimes on top of the muscle cells, and communicate via synapses (gaps across which chemical signals flow) with motor nerve cells, which lie mostly between the bases of the muscle cells. Some form a simple nerve net. Interstitial cells, which are unspecialized and can replace lost or damaged cells by transforming into the appropriate types. These are found between the bases of muscle cells. In addition to epitheliomuscular, nerve and interstitial cells, the inward-facing gastroderm ("stomach skin") contains gland cells that secrete digestive enzymes. In some species it also contains low concentrations of cnidocytes, which are used to subdue prey that is still struggling. The mesoglea contains small numbers of amoeba-like cells, and muscle cells in some species. However, the number of middle-layer cells and types are much lower than in sponges.

== Reception == Decay received a weak but overall positive reception from the video games industry's critics. Writing for GameSpot, Doug Radcliffe argued that Decay was "impressive", praising the design of puzzles required players to work together, as well as the way in which the ranking system discouraged players from competing against each other. GameSpy's David Hodgson was more reserved in his views of the game; although describing it as "great fun", he noted that it could become "tedious, with one member waiting for minutes at a time, while the other scratches their head, then completes an objective". In addition, Hodgson felt that the more puzzle-orientated nature of Decay left the action elements "a little muted compared to Gordon's single player quest". Allgame described Decay as an "added bonus" for the PlayStation 2 version of Half-Life, but noted that as the game was designed for two players, it significantly suffered when a single player attempts to play it by switching between two characters, a point that both GameSpy and GameSpot agreed on. In his review for IGN, critic Doug Perry felt that Decay was "neat in its own limited way", but that it was more of a distraction from the main game, more "a complementary cup of vegetable soup than a piping hot main dish of New York steak". While The Electric Playground reviewer Steve Smith stated that the control scheme for the PlayStation 2 version of Half-Life "is about the best we have seen on the PS2 or any console", he concluded that although Decay was a "nice add-on", it was "no reason to buy this port".

Sources: en.wikipedia.org

Notes from published material

This stage of the aerobic system occurs on the cristae (infoldings of the membrane of the mitochondria). The reaction of each NADH in this electron transport chain provides enough energy for 3 molecules of ATP, while reaction of FADH2 yields 2 molecules of ATP. This means that 10 total NADH molecules allow the regeneration of 30 ATP, and 2 FADH2 molecules allow for 4 ATP molecules to be regenerated (in total 34 ATP from oxidative phosphorylation, plus 4 from the previous two stages, producing a total of 38 ATP in the aerobic system). NADH and FADH2 are oxidized to allow the NAD+ and FAD to be reused in the aerobic system, while electrons and hydrogen ions are accepted by oxygen to produce water, a harmless byproduct.

The British implemented a scorched earth policy under which they targeted everything within the controlled areas that could give sustenance to the guerrillas, making it harder for them to survive. As British troops swept the countryside, they systematically destroyed crops, poisoned wells, burned homesteads and farms, and interned Boer and African men, women, children and workers in concentration camps. The British established mounted raiding columns in support of sweeper columns. These were used to rapidly follow and relentlessly harass the Boers to delay them and cut off escape, while the sweeper units caught up. Many of the 90 or so mobile columns formed by the British to participate in such drives were a mixture of British and colonial troops, but they also had a large minority of armed Africans. The number of armed Africans serving with these columns has been estimated at 20,000. The British Army made use of Boer auxiliaries who had been persuaded to change sides and enlist as "National Scouts". Serving under General Andries Cronjé (1849–1923), the National Scouts were despised as joiners but numbered a fifth of the fighting Afrikaners by the end of the War. The British utilised armoured trains to deliver rapid reaction forces much more quickly to incidents (such as Boer attacks on blockhouses and columns) or drop them off ahead of retreating Boer columns.

== Treatment == Treatment of diving barotrauma depends on the symptoms, which depend on the affected tissues. Lung over-pressure injury may require a chest drain to remove air from the pleura or mediastinum. Recompression with hyperbaric oxygen therapy is the definitive treatment for arterial gas embolism, as the raised pressure reduces bubble size, the reduced blood inert gas concentration may accelerate inert gas solution, and high oxygen partial pressure helps oxygenate tissues compromised by the emboli. Care must be taken when recompressing to avoid a tension pneumothorax. Barotraumas that do not involve gas in the tissues are generally treated according to severity and symptoms for similar trauma from other causes.

Skin and skin structure Infections This medication can be used to treat skin and skin structure infections caused from beta-lactamase-producing strains of S. aureus, Enterobacter spp., E. coli, Klebsiella spp. (including K. pneumoniae), P. mirabilis, B. fragilis, and Acinetobacter calcoaceticus. Examples of skin conditions treated with ampicillin-sulbactam are moderate to severe diabetic foot infections and type 1 Necrotizing fasciitis, commonly referred to as "flesh-eating bacteria".

CH3C(O)CO−2 → "CH3CO−" + CO2 This irreversible reaction is catalyzed by the pyruvate dehydrogenase complex. It consists of three enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2), dihydrolipoamide dehydrogenase (E3), six cofactors: thiamine pyrophosphate (TPP), lipoamide, coenzyme A (CoA), flavin adenine dinucleotide (FAD), magnesium ion, and one co-substrate: nicotinamide adenine dinucleotide (NAD+). Pyruvate converts the thiazole ring of TPP to its hydroxyethyl derivative, concomitant with decarboxylation. With the catalysis of E2, TPP-CH(OH)CH3 reacts with the S-S bond of lipoamide to produce thioester bond (acetyl dihydrolipoamide. The acetyl reacts with CoA-SH to give Acetyl-CoA and dihydrolipoamide. The latter is oxidized to lipoamide (with S-S bond) by FAD.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a selective androgen receptor modulator?

No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.

Why did clinical development stop?

Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.

Is cardarine approved for medical use?

No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Network